Tracy McCarty
Head of Investor Relations
Replay available
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q4 2025 earnings conference call, held 2026-02-23. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Alexander Hardy
Chief Executive Officer
Brian Mueller
Chief Financial Officer
Kristen Hubbard
Chief Commercial Officer
Greg Freiberg
Chief R&D Officer
Mohit Bansal
Analyst, Wells Fargo
Chris Raymond
Analyst, Raymond James
Phil Netto
Analyst, TD Cullen
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Biomarin Pharmaceutical Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.996 Thank you for standing by. My name is Kate and I will be your conference operator today. 00:00:04.996 -- 00:00:10.142 At this time, I would like to welcome everyone to the Biomarine Pharmaceutical 00:00:10.142 -- 00:00:15.027 fourth quarter and full year 2025 conference call. 00:00:15.027 -- 00:00:18.831 All lines have been placed on mute to prevent any background noise. 00:00:18.831 -- 00:00:22.335 After the speaker's remarks, there will be a question and answer session. 00:00:22.335 -- 00:00:27.641 If you would like to ask a question during this time, simply press star followed 00:00:27.641 -- 00:00:30.355 by the number one on your telephone keypad. 00:00:30.355 -- 00:00:33.478 If you would like to withdraw your question, press star one again. 00:00:33.478 -- 00:00:38.504 Thank you. I would now like to turn the call over to Tracy McCarty, Head 00:00:38.504 -- 00:00:42.288 of Investor Relations. Please go ahead. 00:00:42.288 -- 00:00:45.071 Thank you, Operator, and starting on slide two. 00:00:45.071 -- 00:00:49.135 To remind you, this non-confidential presentation contains forward-looking statements 00:00:49.135 -- 00:00:54.181 about the business prospects of Biomarin Pharmaceutical Inc., including expectations 00:00:54.181 -- 00:00:58.410 regarding Biomarin's financial performance, commercial products, and potential future 00:00:58.410 -- 00:01:02.477 products in different areas of therapeutic research and development. 00:01:02.477 -- 00:01:07.164 Results may differ materially depending on the progress of Biomarin's product programs, 00:01:07.164 -- 00:01:12.312 actions of regulatory authorities, availability of capital, future actions in the pharmaceutical 00:01:12.312 -- 00:01:17.541 market, and developments by competitors, an...